Zafgen Inc. Attempts To Double After Positive Results For Obesity Drug

Zafgen Inc. ZFGN shares are trading higher by $4.48 at $10.10 in Wednesday's session. The Street is rewarding the company for its Phase 3 obesity trial that achieved co-primary efficacy endpoint. After a sharply higher open, it retreated only $0.13 to $7,33 before resuming its move higher. So far, the issue has reached $11.88 before falling back its current level. The issue has been attempting to recover from the drubbing it took on December 2, when it fell from $15.93 to $6.28. the catalyst for that decline a was a patient death in a clinical update for Beforanib.